The Belt and Road: Cooperation, Harmony and Win-Win
products

Products

Tofacitinib CAS:477600-75-2 Manufacturer Supplier

Tofacitinib is the first small molecule kinase inhibitor approved for the treatment of RA. Tofacitinib is an inhibitor of the four subtypes of Janus kinase (JAK): JAK1, JAK2, JAK3, and Tyk2.Tofacitinib acts by inhibiting the phosphorylation and activation of signal transducers and activators of transcription (STATs), thereby suppressing the production of inflammatory mediators in joint tissue.


Product Detail

Product Tags

Application and Effect

Tofacitinib is a drug for the treatment of rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. It is an inhibitor of the enzyme Janus kinase 3 (JAK3), which means that it interferes with the JAK-STAT signaling pathway that transmits information outside the cell into the cell nucleus, influencing DNA transcription. Recently it has been shown in a murine model of established arthritis, tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue.This efficacy in this disease model correlated with the inhibition of both JAK1 and 3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.

Product Sample

图片418(1)
图片419(1)

Product Packing:

图片18

Additional Information:

Composition C16H20N6O
Assay 99%
Appearance Off-white powder
CAS No. 477600-75-2
Packing 25KG
Shelf Life 2 years
Storage Store in cool and dry area
Certification ISO.

  • Previous:
  • Next:

  • Write your message here and send it to us